The intricate relationship between PNH and aplastic anemia rests on one idea: when the immune system attacks the bone marrow in aplastic anemia, blood stem cells carrying a particular mutation can escape the attack and expand. Those surviving cells produce red cells that complement, part of the immune system, easily destroys, which is the hallmark of paroxysmal nocturnal hemoglobinuria (PNH). That is why the two conditions so often appear together, or one develops years after the other.
Both are rare, serious and treatable. Understanding how they connect helps patients make sense of their test results and helps clinicians choose the right monitoring and treatment.
What Are PNH and Aplastic Anemia?
Aplastic anemia
Aplastic anemia is a form of bone marrow failure in which the marrow becomes empty of blood-forming cells. The result is pancytopenia: low red cells, low white cells and low platelets together. In most acquired cases, T cells of the immune system attack the hematopoietic stem cells, the parent cells of all blood cells. Many cases have no identifiable trigger, though some follow hepatitis, certain drugs or exposure to toxins such as benzene.
PNH
PNH is an acquired hematologic disorder caused by a mutation in the PIGA gene in a blood stem cell. This gene is needed to build the GPI anchor, a molecule that attaches certain proteins to the cell surface. Without it, cells lose two protective proteins, CD55 and CD59, which normally shield them from complement. The affected erythrocytes are then broken down inside blood vessels, well before their normal lifespan of about 120 days.
Why the Two Conditions Are Linked
The leading explanation is immune escape. The immune attack in aplastic anemia is thought to target something displayed on the surface of normal stem cells, likely involving GPI-anchored structures. Stem cells with a PIGA mutation lack that target, so they survive while their normal neighbors are destroyed. Over time, the PNH clone makes up a growing share of the blood.
This produces a spectrum rather than two separate boxes:
- Aplastic anemia with a small PNH clone found only on sensitive testing and no hemolysis.
- Aplastic anemia with a clone large enough to cause some hemolysis.
- Classic PNH with marked hemolysis and a marrow that is working.
- PNH arising years after treatment for aplastic anemia as the clone expands.
Small PNH clones are found in a substantial proportion of people with aplastic anemia. Their presence is not a separate disease, but it guides monitoring, since the clone can grow and start to cause hemolysis or thrombosis.
Comparing the Clinical Features
| Feature | Aplastic anemia | Classic PNH |
|---|---|---|
| Core problem | Marrow fails to produce cells | Complement destroys unprotected red cells |
| Blood counts | Low red cells, white cells and platelets | Anemia; white cells and platelets may be low |
| Reticulocytes (young red cells) | Low | Often raised as the marrow compensates |
| Hemolysis markers (LDH, bilirubin) | Normal | Raised LDH, low haptoglobin |
| Urine | Normal | Dark or cola-colored urine, often in the morning |
| Blood clots | Not typical | Major risk, often in unusual sites |
| Marrow | Empty (hypocellular) | Usually normal or busy |
Aplastic anemia typically presents with fatigue, infections and easy bruising or bleeding. PNH adds signs of hemolysis: jaundice, dark urine, abdominal pain, difficulty swallowing and, in men, erectile dysfunction, which relate to free hemoglobin mopping up nitric oxide. The most dangerous complication of PNH is thrombosis, including clots in the liver veins (Budd-Chiari syndrome), abdominal veins and brain veins. Over time, kidney damage and pulmonary hypertension can also develop.
How Doctors Diagnose Each Condition
Testing moves from general to specific:
- Complete blood count and reticulocyte count to look at all three cell lines and marrow output.
- Hemolysis tests, including LDH, bilirubin and haptoglobin, plus a direct antiglobulin (Coombs) test, which is negative in PNH.
- Flow cytometry of blood to measure cells lacking GPI-anchored proteins. This is the standard test for PNH and detects even small clones.
- Bone marrow biopsy to confirm an empty marrow in aplastic anemia and exclude leukemia or myelodysplasia.
Severity of aplastic anemia is graded by marrow cellularity and blood counts. Severe disease is defined by a marrow cellularity under 25% plus at least two of: neutrophils below 0.5 × 10⁹/L, platelets below 20 × 10⁹/L, or a very low reticulocyte count. Neutrophils below 0.2 × 10⁹/L define very severe disease. Everyone diagnosed with aplastic anemia should have PNH flow cytometry, and it is usually repeated periodically.
Treatment and Long-Term Management
Treating aplastic anemia
For severe disease in younger, fit patients with a matched sibling donor, hematopoietic stem cell transplantation is often first choice and can be curative. For others, immunosuppressive therapy with antithymocyte globulin and cyclosporine is standard, frequently combined with eltrombopag, a medicine that stimulates remaining stem cells. Transfusions, infection prevention and iron management support patients throughout.
Treating PNH
People with significant hemolysis are treated with complement inhibitors. Eculizumab and ravulizumab block complement protein C5 and greatly reduce hemolysis and clot risk. Newer agents act earlier in the complement pathway, such as pegcetacoplan (C3) and oral inhibitors including iptacopan. Because complement inhibition raises the risk of meningococcal infection, vaccination is required before starting, and patients carry a warning card. Anticoagulation is used for anyone who has had a clot.
When both are present
Treatment follows whichever problem dominates. If the marrow failure is severe, immunosuppression or transplant comes first. If hemolysis is prominent, a complement inhibitor is added. Transplantation is the only approach that can cure both. More background on marrow conditions is available in our bone marrow hub and in our guide to hematology and blood health.
Key Takeaways
- PNH clones survive the immune attack that causes aplastic anemia, so the conditions often overlap.
- Flow cytometry detects PNH; bone marrow biopsy confirms aplastic anemia.
- Aplastic anemia causes low counts; PNH adds hemolysis and a serious clotting risk.
- Complement inhibitors control PNH, while immunosuppression or transplant treats marrow failure.
- Anyone with aplastic anemia needs periodic PNH testing because clones can grow.
Frequently Asked Questions
Can aplastic anemia turn into PNH?
Yes. A small PNH clone present at diagnosis can expand after the marrow recovers, especially after immunosuppressive therapy. This is why regular flow cytometry is part of follow-up.
Is PNH inherited?
No. The PIGA mutation arises in a single blood stem cell during life and is not passed to children. PNH is an acquired condition, not a family trait.
Is a small PNH clone dangerous?
A small clone without hemolysis usually needs monitoring rather than treatment. It may even suggest the marrow failure is immune-driven and likely to respond to immunosuppression. Treatment is considered if the clone grows or causes symptoms.
Why does PNH cause blood clots?
Complement attack on unprotected platelets and blood cells, free hemoglobin from hemolysis, and loss of nitric oxide all make the blood more prone to clot. Complement inhibitors substantially reduce this risk.
